×
ADVERTISEMENT

JULY 28, 2023

FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment


Originally published by our sister publication Infectious Disease Special Edition

The FDA expanded the indication to remdesivir (Veklury, Gilead) for use in COVID-19 patients with severe renal impairment, including those on dialysis. 

With this approval, remdesivir is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. About 37 million people in the United States are estimated to have chronic kidney disease (CKD) and at increased